Loren Stefan 4/A

What Happened Loren Stefan, a consultant to Cellectar Biosciences, was granted a derivative equity award on July 8, 2026: an option/award covering 15,000 shares with an exercise price reported as $0.00. The grant is a compensatory equity award (not a market purchase or sale), and the filing was amended to correct the exercise price reported in the original Form 4.

Key Details

• Transaction date: 2026-07-08; Award type: Grant/Award (derivative) for 15,000 shares at $0.00 exercise price.
• Vesting: This option shall vest in full on July 8, 2027, subject to continued service through that date (footnote).
• Filing: Amended Form 4 filed 2026-07-10 to correct the exercise price reported in the original Form 4 filed July 8, 2026.
• Shares owned after transaction: Not specified in this amended filing.
• No sale or exercise reported — this is a grant subject to future vesting.

Context This is a compensatory equity grant to a consultant rather than a market purchase or sale. Because it is a derivative award that vests in the future, it does not represent immediate share ownership or liquidation. The amendment simply corrects the exercise-price detail in the original filing; it does not indicate any subsequent trading.